

Clinical Course Of Disease In Participants With FA-CM

NCT06865482

Status	RECRUITING
Sponsor	Lexeo Therapeutics
Enrollment	65 participants

Key Eligibility Criteria

Inclusion (4)

- Male or female, ages e6 years at the time of signing the informed consent (and assent, if applicable).
- Diagnosis of FA, based on clinical phenotype and genotype (GAA expansion on both alleles or compound heterozygous), with onset of FA occurring at d25 years of age
- Confirmed left ventricular hypertrophy (LVH)
- Left ventricular ejection fraction e40%

Exclusion (8)

- Presence of other form(s) of CM contributing to heart failure (HF), clinically significant cardiac anatomic abnormality or congenital cardiac malformation, clinically significant coronary artery, uncorrected, hemodynamically significant primary structural valvular disease not due to CM
- Currently receiving intermittent or continuous intravenous (IV) inotrope infusion, presence of a ventricular assist device, or history of prior heart transplantation
- Contraindication to cMRI, participants \<12 years of age who cannot complete the cMRI without sedation will instead undergo ECHOs and are exempt from this criterion.
- Prior organ transplantation
- Initiation of cardiac resynchronization therapy (CRT) within 6 months prior to screening.

... and 3 more (see full listing online)

Locations (10 total)

University of California San Diego, La Jolla, California, United States
University of South Florida, Tampa, Florida, United States
Indiana University - Riley Children's Health, Indianapolis, Indiana, United States
... and 7 more locations

<https://clinicaltrials.gov/study/NCT06865482>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).